VBL Therapeutics, Ltd. (VBLT)

Oncology Corporate Profile

Stock Performance

3.2300
0.0300

HQ Location

6 Jonathan Netanyahu St.
Or Yehuda, Israel 60376

Company Description

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer.¥_

Website: http://www.vblrx.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
VB-111anti angiogenic agentGlioblastoma Multiforme (GBM)III
VB-111anti angiogenic agentOvarian cancerII
VB-111anti angiogenic agentThyroid cancerII
VB-111anti angiogenic agentVarious cancer typesI

View additional information on product candidates here »

Pipeline image

Source


http://www.vblrx.com

Recent News Headlines

VBL Therapeutics to Present at the H.C. Wainwright NASH Investor Conference

3/28/2017 11:00 am

[GlobeNewswire] - TEL AVIV, Israel, March 28, 2017-- VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced ...

VBL Therapeutics Announces Fourth Quarter and Year End 2016 Financial Results

3/27/2017 11:03 am

[GlobeNewswire] - Interim analysis in the GLOBE pivotal study is expected in mid-2017, with top-line data expected in early 2018 Phase 3 Study of VB-111 in Ovarian Cancer Currently Expected to Begin Enrollment in the Second ...

VBL Therapeutics to Host a Key Opinion Leader Event on Novel New Targets and Immunotherapeutic Approaches to Oncology

3/23/2017 11:00 am

[GlobeNewswire] - TEL AVIV, Israel, March 23, 2017-- VBL Therapeutics announced today that it will be hosting a Key Opinion Leader breakfast on new targets and immunotherapeutic approaches to oncology, on April 6, 2017 ...

VBL Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference

3/15/2017 11:00 am

[GlobeNewswire] - TEL AVIV, Israel, March 15, 2017-- VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced ...

VBL Therapeutics to Present at the 29th Annual ROTH Conference

3/7/2017 12:00 pm

[GlobeNewswire] - TEL AVIV, Israel, March 07, 2017-- VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced ...

VBL Therapeutics to Report Full-Year 2016 Financial Results on March 27

3/2/2017 01:00 pm

[GlobeNewswire] - TEL AVIV, Israel, March 02, 2017-- VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced ...

VBL Therapeutics Reports Full Data for VB-111 Monotherapy in Phase 2 Trial for Recurrent Thyroid Cancer

2/21/2017 12:00 pm

[GlobeNewswire] - TEL AVIV, Israel, Feb. 21, 2017-- VBL Therapeutics, announced today full results from its exploratory Phase 2 study of VB-111 in patients with advanced, differentiated thyroid cancer. The data will be ...

VBL Therapeutics to Present at the 2017 BIO CEO & Investor Conference

2/6/2017 01:00 pm

[GlobeNewswire] - TEL AVIV, Israel, Feb. 06, 2017-- VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced ...

VBL Therapeutics Announces Publication of Research on a Potential Novel Immuno-Oncology Target

1/31/2017 09:00 pm

[GlobeNewswire] - TEL AVIV, Israel, Jan. 31, 2017-- VBL Therapeutics, announced today the publication of a paper discussing MOSPD2, a potential novel immuno-oncology target. The paper, entitled, "Identification of ...

VBL Therapeutics Provides Year End 2016 Corporate Update

1/9/2017 12:00 pm

[GlobeNewswire] - TEL AVIV, Israel, Jan. 09, 2017-- VBL Therapeutics, provides corporate update and reviews anticipated highlights for 2017.. Following positive EOP2 meeting on VB-111 in ovarian cancer, VBL plans to launch ...

VBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE Study

1/6/2017 12:05 pm

[at noodls] - TEL AVIV, Israel, Jan. 06, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today that it has completed enrollment in the GLOBE Phase 3 study evaluating the efficacy of its lead candidate ...

VBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE Study

1/6/2017 12:00 pm

[GlobeNewswire] - TEL AVIV, Israel, Jan. 06, 2017-- VBL Therapeutics, announced today that it has completed enrollment in the GLOBE Phase 3 study evaluating the efficacy of its lead candidate ofranergene obadenovec in patients ...

VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM

12/5/2016 12:00 pm

[GlobeNewswire] - TEL AVIV, Israel, Dec. 05, 2016-- VBL Therapeutics, today announced that the independent Data Safety Monitoring Committee met to conduct its first safety review of the Phase 3 GLOBE Study investigating ...

VBL Therapeutics Announces Overall Survival Data for VB-111 Monotherapy in Phase 2 Study for Recurrent Thyroid Cancer

11/29/2016 12:00 pm

[GlobeNewswire] - The study met its primary endpoint, demonstrating disease stabilization and safety, along with a dose-response Newly released data show evidence of an overall survival benefit for patients treated with ...

VBL Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29

11/23/2016 03:05 pm

[GlobeNewswire] - TEL AVIV, Israel, Nov. 23, 2016-- VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced ...